top of page
Search

Transarterial Chemoembolization (TACE) Market Development Trends, Opportunities, Companies 2027

Writer: celina reddencelina redden

Transarterial Chemoembolization (TACE) Market Research Report: By Procedure Type (Conventional TACE, DEB-TACE), Indication (Unresectable HCC, Early-Stage HCC), Product Type (Chemotherapeutic Agents, Radiotherapeutic Agents, Drug-eluting Particles), End-User (Hospitals & Clinics, Cancer Research Centers) - Forecast to 2027

Market Forecast

Registering a CAGR of 8.57%, Transarterial Chemoembolization (TACE) Market is expected to grow from USD 1559.20 Million in 2018 to USD 2777.22 Million by 2025.

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs mainly due to chronic liver disease and cirrhosis. It is the third leading cause of cancer deaths worldwide, with over 500,000 people affected. Transarterial chemoembolization is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional TACE is considered as a standard treatment for HCC

Market Influencer

Improvement in the reimbursement scenario is impacting the growth of the Transarterial Chemoembolization (TACE) Market . The cost of sorafenib is reimbursed by Taiwan’s National Health Insurance (NHI) administration with the TACE procedure. Moreover, Lipiodol is approved for National Health Insurance reimbursement for transcatheter arterial chemoembolization for HCC.

Key Players

  • Advaxis Inc. (US)

  • Baxter (US)

  • Bellicum Pharmaceuticals, Inc. (US)

  • Boston Scientific Corporation (US)

  • Cook (US)

  • Hikma Pharmaceuticals PLC (UK)

  • Isofol Medical AB (Sweden)

  • Nippon Kayaku Co., Ltd. (Japan)

  • Novartis (Switzerland)

  • Pfizer (US)

  • Sirtex SIR-Spheres Pty Ltd. (Australia)

  • Spectrum Pharmaceuticals, Inc. (US)

  • Jiangsu Hengrui Medicine Co., Ltd (China)

Segmentation

By Procedure Type

  • Conventional TACE: Conventional TACE dominated the Transarterial chemoembolization (TACE) market as it is one of the oldest procedures used in HCC cases. Conventional TACE involves the infusion of chemotherapeutic drugs blended with lipiodol and embolic agents into the cancer-feeding artery

  • DEB-TACE: This segment is expected to witness the fastest growth. DEB-TACE allows higher concentrations of drugs to the target tumor and lower systemic concentrations, compared with conventional TACE

By Indication

  • Unresectable HCC: TACE is a major treatment modality for unresectable HCC. The liver tumor which is not eligible for resection therapy given the extent of disease is considered as unresectable HCC

  • Early-Stage HCC: In case of early-stage HCC, TACE is recommended if resection or local ablation is not feasible

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

 
 
 

Recent Posts

See All

Comments


bottom of page